Our study aimed to apply meta-analysis to clarify whether K-ras mutation might affect the prognosis of CRC patients who received adjuvant chemotherapy and could be utilized as a predictive biomarker for chemotherapy. The gene discussed is KRAS; the disease is colorectal carcinoma.